Four pharmaceutical industry leaders are poised to report second-quarter results next week, and one key analyst sees the relatively good print from Johnson & Johnson as a good signal for the group…
The June 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
The June 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Keep in mind that short sellers betting against big pharma are taking on an added risk. They have to pay out the ongoing high dividends on top of the cost of borrowing…
Nektar Therapeutics (NASDAQ: NKTR) saw its shares get nearly halved in Monday’s session after the company released preliminary data from its early stage cancer study. The preliminary results presented at the 2018…
The May 15 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
This year marks the 54th annual meeting of the American Society of Clinical Oncology, the world’s largest clinical cancer conference.
One good idea now may be to take some profit on winners and look for some contrarian ideas that could have solid upside and a degree of safety.
The April 30 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
LendingClub, Coca-Cola, Acadia Pharmaceuticals, and Bristol-Myers Squibb all posted new 52-week lows Wednesday.
The April 13 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
24/7 Wall St. has put together a preview of AbbVie, Eli Lilly and some of the other top pharma and biotech companies reporting their latest quarterly results in the coming week.
Mattel, NXP Semiconductor, Bristol-Myers, and Kraft Heinz all posted new 52-week lows Friday.
The top analyst upgrades, downgrades and other research calls from Tuesday include Bristol-Myers Squibb, Chesapeake Energy, Coca-Cola, Dropbox, GrubHub, Merck, National Oilwell Varco, Netflix and Twitter.
Lung cancer may have just met a new standard of care. On top of that, it would be considered a new standard as a first line of care in lung cancer and longer overall…
